ArticleScientific reports2025
Early detection of Alzheimer's disease progression: comparative evaluation of deep learning models.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Sigma-1 Receptor Ligand Blarcamesine (ANAVEX 2-73) for Alzheimer's Disease: A Systematic Review.CNS drugs · 2026Pooled it
- Navigating the Artificial Intelligence Revolution in Clinical Neurology: A New Multidisciplinary Task Force Within the European Academy of Neurology.European journal of neurology · 2026Article
- TriFusion-ADFormer: a deep learning framework for early Alzheimer's disease detection using MRI and cognitive metrics.Frontiers in artificial intelligence · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The accurate diagnosis and monitoring of Alzheimer's disease (AD) is particularly critical given the increasing number of cases worldwide. Improving forecasting precision using deep learning models on neuroimaging biomarkers can aid in more accurately predicting Alzheimer's associated disease progression. In this work, we assess two separate 3D Convolutional Neural Network (CNN) models for binary AD progression classification based on MRIs of the brain's structure. The first model uses a whole volume approach and processes entire MRI scans, thus requiring little computational power and minimal preprocessing compared to other methods. Alternatively, the second model applies voxel-level scrutiny by examining specific pre-defined brain regions that have statistically significant grey matter volume differences from cohort analyses. MRI preprocessing includes N4 bias field correction, segmentation of tissues, alignment to the Montreal Neurological Institute (MNI) space, and Gaussian smoothing for homogenization of image quality. For the region-focused model, feature extraction is driven by neuroanatomy, concentrating on areas where AD shows shrinkage changes. The full-volume CNN achieved a 94% validation accuracy, demonstrating high computational efficiency with its simpler architecture, while the region-guided model reached 95% accuracy by leveraging more complex domain-specific structural biomarkers, highlighting enhanced performance at the cost of increased model intricacy. This study highlights the potential of combining deep learning frameworks with neuroimaging biomarkers to improve early detection and monitoring of AD. While our findings highlight the value of guided feature selection and volumetric data evaluation in improving diagnostic precision, they are derived solely from the ADNI dataset and must be validated on more diverse clinical populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.